Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, L. Austin Doyle et al.|JAMA Oncology|2020Cited by 106
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancersYoshihisa Kobayashi, Pasi A. Jänne, Chhayheng Chhoeu et al.|Nature|2022Cited by 62
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance statusJoao V. Alessi, Mark M. Awad, Biagio Ricciuti et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 58